Results obtained after the surgical treatment of Graves’ disease depending on the levels of anti-thyroid antibodies
DOI:
https://doi.org/10.30978/GS-2021-1-36Keywords:
antibodies to the thyroid‑stimulating hormone receptors, Graves’ disease, subtotal thyreoidectomy, thyroidectomyAbstract
Graves' disease (GD) is a hereditary autoimmune disease which is characterized by persistent abnormal hypersecretion of thyroid hormones and thyrotoxicosis syndrome development. GD affects from 0.5 % to 2.0 % of population in different regions. 46 % of these patients develop ophthalmopathy. GD is a common cause of disabilities in patients under 60 years of age. In recent years, the incidence of GD in Ukraine has increased by 9.9 % — from 106.2 to 117.9 per 100,000 individuals. This can be connected with the improved diagnostic possibilities and active disease detection as well as with the increased number of autoimmune thyroid disorders. The recent studies focus on prevention of specific complications and recurrences of GD after surgery.
Objective — to compare the levels of antibodies to the thyroid‑stimulating hormone receptors (TSHR‑Ab) during different postoperative periods as well as the incidence of early and late complications depending on the surgical technique used for the treatment of GD.
Materials and methods. The results of surgical treatment of 130 patients, with GD were compared. 29 male patients and 101 female patients aged from 19 to 76 (average — 44.1 ± 3.2 years), receiving their treatment for GD in Kyiv Center of Endocrine Surgery during 2010—2018, were randomly selected and divided into two groups. At the time of operation the duration of disease was from 1 to 30 years (average — 4.6 ± 1.2 years). Group 1 included 65 patients that underwent total thyreoidectomy (TT) and group 2 included 65 patients that underwent subtotal thyreoidectomy (ST). The following parameters were compared: surgery duration, the incidence of early postoperative complications, including bleedings and damage to the recurrent laryngeal nerves, and late outcomes of surgical treatment (persistent hypoparathyreoidism disorder and disorder recurrences) depending on the method of surgery (ST or TT). Furthermore, the patterns of the TSHR‑Ab level reduction were studied for different postoperative periods.
Results. The comparison of surgical outcomes following TТ and ST didn’t reveal any statistically significant differences in such evaluation criteria as the average surgery duration, the average volume of intraoperative blood loss and the average duration of the postoperative inpatient treatment. The comparative assessment of the thyroid stump volume and the average amount of drained discharge showed statistically significant differences for TТ. It allows considering TТ as a surgery which causes less complications than ST. The studied parameters of early postoperative complications had no significant differences for ST and TТ. The long‑term (5 years) postoperative level of TSHR‑Ab was statistically significantly lower in patients after TT and made up 1.15 ± 0.13 IU/L (thus corresponding to the normal level).
Conclusions. Total thyroidectomy is an optimal surgical technique and is more appropriate compared with subtotal thyroid gland resection. It should be noted that TT provides lower risk of complications due to significantly lower level of TSHR‑Ab in late postoperative period.
References
Buldygina YV. Does the name «diffuse toxic goiter» reflect the structural state of the thyroid gland in this nosology? International Journal of Endocrinology. 2020; 16(3):215-20.
Davies TF, Andersen S, Latif R, Nagayama Y, et al. Graves' disease. Nat Rev Dis Primers. 2020 Jul;6(1):52.
Dawon Park, Hong Kyu Kim, Hoon Yub Kim. Transoral robotic thyroidectomy. Int J Thyroidol. 2018 May;11(1):26-30.
Ehlers M, Schott M, Allelein S. Graves' disease in clinical perspective. Front Biosci (Landmark Ed). 2019 Jan; 24 : 35-47.
Fadeev VV. Conclusions, based on the clinical guidelines of the European Thyroid Association for the diagnosis and treatment of thyrotoxicosis in the Graves disease 2018, Clinical and experimental thyroidology. 2020;16(1):4-20.
Garstka M, Kandil E, Saparova L, et al. Surgery for Graves' disease in the era of robotic-assisted surgery: a study of safety and feasibility in the Western population. Langenbecks Arch Surg. 2018 Nov;403(7):891-6.
Kahaly GJ, Bartalena L, Hegeds L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018 Aug;7(4):167-86.
Kahaly GJ, Olivo PD. Graves’ Disease. N Engl J Med. 2017 Jan;376(2):184.
Kiyaev AV, Savelyev LI, Gerasimova LY. The value of determining antibodies to the thyroid-stimulating hormone receptor when canceling antithyroid therapy for the Graves disease in children. Problems of endocrinology. 2007; 53(6):24-6.
Kovalenko AE. Thyroidectomy and postoperative hypothyroidism, Health of Ukraine, 2008;8/1 : 37-8.
Latif R, Mezei M, Morshed SA, Ma R, Ehrlich R, Davies TF. A modifying autoantigen in Graves' disease. Endocrinology. 2019 May;160(5):1008-20.
Loick J, Schulz HG, Rupp KD, Hohlfcach G. Is the thyroidectomy a surgical standard procedure for therapy of Graves disease? Zen-tralbl Chir. 2005;368.
Miteva MZ, Nonchev BI, Orbetzova MM, Stoencheva SD. Vitamin D and autoimmune thyroid diseases — review. Folia Med (Plovdiv) 2020;62(2):223-9.
Mohan V, Lind RJ. A review of treatment options for Graves' disease: why total thyroidectomy is a viable option in selected patients. Community Hosp Intern Med Perspect. 2016 Sep;6(4):32369.
Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020 Mar;271(3):21-93.
Pashentseva AV, Verbovoy AF. Diffuse toxic goiter, Clinical medicine. 2017;9 : 780-8.
Rapoport B, Aliesky HA, Chen C-R, McLachlan SM. Evidence that TSH receptor A-subunit multimers, not monomers, drive antibody affinity maturation in Graves’ disease. J Clin Endocrinol Metab. 2015;100 : 871-5.
Reinhart HA, Snyder SK, Stafford SV, et al. Same day discharge after thyroidectomy is safe and effective. Surgery. 2018;164(4):887-94.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421.
Rubio GA, Koru-Sengul T, Vaghaiwalla TM, Parikh PP, Farra JC, Lew JI. Postoperative outcomes in Graves' disease patients: Results from the Nationwide Inpatient Sample Database. Thyroid. 2017 Jun;27(6):825-31.
Savchenko AA, Dogadin SA, Dudina MA, Matsynina VP. Clinical and immunological parameters and their relationship with thyroid status in patients with the Graves disease, depending on the level of autoantibodies to thyroperoxidase. Endocrinology problems. 2016;62(1):4-9.
Stathopoulos P, Gangidi S, Kotrotsos G, Cunliffe D. Graves' disease: a review of surgical indications, management, and complications in a cohort of 59 patients. Int J Oral Maxillofac Surg. 2015;44(6):713-17.
Smith TJ, Hegeds L. Graves' Disease. N Engl J Med. 2016 Oct;375(16):1552-65.
Sun Y Lee. Quality of life is worse at 6-10 years after radioactive iodine treatment of Graves’ disease as compared with antithyroid drugs or Surgery. Clinical Thyroidology. 2019 Apr;31(4):144-7.
Tronko MD, Kovalenko AE, Tarashchenko UM, Ostafiychuk MV. Surgical aspects of thyrotoxicosis and chronic autoimmune thyroiditis (literature review and own research), Journal of the National Academy of Medical Sciences of Ukraine, 2018;24(3-4):258-67.
Wang W, Xia F, Meng C, Zhang Z, Bai N, Li X. Prediction of permanent hypoparathyroidism by parathyroid hormone and serum calcium 24h after thyroidectomy. Am J Otolaryngol. 2018;39(6):746-50.
Vital D, Morand GB, Meerwein C, et al. Early timing of thyroidectomy for hyperthyroidism in Graves’ disease improves biochemical recovery. World J Surg. 2017;41(10):2545-50.
